MARC details
| 000 -LEADER |
|---|
| fixed length control field |
08419namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20250223033315.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
241019s2023 |||a|||f ||m| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposite |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.99465 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.99465 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.19.04.M.Sc.2023.Ro.C |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Rowida Melegy Abdelghani Elmelegy, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Clinico-pathological characteristics and treatment outcomes of patients with platinum sensitive metastatic and/or recurrent epithelial ovarian cancer / |
| Statement of responsibility, etc. |
by Rowida Melegy Abdelghani Elmelegy ; Prof. Dr.Alfred Elias Namour , Dr. Abdelhamid M.F. Abdelhamid , Dr.Eman Deusoky Taha. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
/الخصائص الإكلينيكية والباثولوجية لمرضى سرطان المبيض الطلائى المنتشر أو المرتجع طبقاً لإستجابته للعلاج بمركبات البلاتينول |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
139 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 122-1393 |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background: In 2020, Global Cancer Statistics reported 300.000 new ovarian cancer (OC) cases & 200.000 <br/>deaths. Standard treatment (ttt) for epithelial OC (EOC) is surgery & platinum based chemotherapy <br/>(CTH). The ttt of recurrent OC (ROC) is CTH based on platinum sensitivity. Although the majority of <br/>patients respond to upfront platinum ttt, they develop recurrences & shorter disease-free intervals <br/>following subsequent ttt. <br/>Objective: To describe the demographic, Clinico-pathological features, ttt regimens, relation between risk <br/>factors & ttt outcome, factors affecting progression free survival (PFS) & overall survival (OS). <br/>Methods: A retrospective study done on 112 platinum sensitive recurrent &/or metastatic EOC cases, <br/>evaluate response & duration of ttt, estimate the platinum free interval (PFI), PFS & OS using Kaplan-<br/>Meier method & comparisons between the factors using the Logrank test at NCI & TCC between <br/>January 2013 & December 2018. <br/>Results: PFI after initial ttt (112cases), 33 cases (29.4%) were platinum sensitive > 24 months (mths) with <br/>PFI (56 mths) & a significant p<0.001, 30 cases (26.8%) were sensitive >12-24 mths (18 mths) with <br/>PFI 18 mths & 49 cases (43.7%) were partially sensitive >6-12 mths (8 mths) with PFI 8 mths. Despite <br/>the response to platinum ttt, most cases show recurrence or mets & >50% turn into platinum <br/>resistance. PFI of 2nd line (80 cases) (73.8%),74 cases received platinum based ttt & only 6 cases <br/>received non-platinum based ttt, 53 (71.6%) out of 74 cases received platinum based only showed <br/>resistance & p= 0.018. <br/> Also, PFS of 1st line was 22 mths compared to 2nd one (4 mths). PFS of 1st line, 49 cases were <br/>platinum sensitive>24 mths with PFS 60 mths & p<0.001, 30 cases were sensitive >12-24 mths with <br/>PFS 27 mths, & 49 cases were partially sensitive with PFS 16 mths. On the contrary, PFS of 2nd line <br/>platinum based ttt, 53 cases progressed in duration <6 mths, with PFS only 2 mths & p=0.001, 21 <br/>cases progressed in duration >6 mths with PFS 15 mths. <br/> OS of all cases was 79 mths, in 1st 2 years was 100%, 3rd year (84.6%) & after 5 years (67.9%). OS of <br/>1st line, 49 cases were platinum sensitive >24 mths with OS 79 mths & p<0.001, 30 cases were <br/>sensitive >12-24 mths with OS 55 mths, & 49 cases were partially sensitive with OS 39 mths. OS of <br/>2nd line CTH, 80 cases out of 112 cases received CTH either platinum or non- platinum based with OS <br/>55 mths & p = 0.030. Although 74 cases that received platinum-based ttt showed longer OS (72 mths) <br/>than other non-platinum (39 mths), but did not show a significant p value >0.05. <br/>Factors affected the PFI, PFS &/or OS, such as co-morbidits, ascites, mass size, mets burden, <br/>abdominal cytology, surgical margin, platinum sensitivity & side effects. <br/>On the contrary, other factors did not influence PFI, PFS or OS, such as age, menopausal &family <br/>history, PS, symptomatic burden, pattern of symptoms, CA125, CEA, type of surgery & FIGO <br/>classification. <br/>Conclusions <br/>In our study we found that, despite the initial response to platinum based CTH for OC patients, most cases <br/>when the tumor shows recurrence or metastasis (mets) do not give the same response & more than 50% turn <br/>into platinum resistance. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
أجريت هذه الدراسة بأثر رجعى على 112 مريضة تم تشخيص إصابتهم بسرطان المبيض الطلائى المرتجع و /أو المنتشر المستجيب لمركبات البلاتينول, وقد تم تقييم الإستجابة والمدة لمزيد من العلاجات , وحساب الفاصل الزمنى الخالى من البلاتين ومعدل البقاء على قيد الحياة بدون تقدم للحالات التى قدمت إلى المعهد القومى للأورام بجامعة القاهرة ومعهد أورام طنطا فالفترة من يناير 2013 حتى ديسمبر 2018.<br/>طبقا للفاصل الزمنى الخالى من البلاتين فإن الحالات التى أظهرت تحسسية كاملة لمركبات البلاتين بعد تلقى الخط الأول للعلاج فى مدة تزيد عن 24 شهرا , كان متوسط الفترة الخالية من البلاتين أطول من الحالات التى أظهرت التحسسية الجزئية (6-12 شهرا) أو حتى التحسسية فى مدة مابين 12 و 24 شهرا مع وجود قيمة p<0.001. كبيرة , على العكس فإن الحالات التى تلقت علاج الخط الثانى , وجدنا أن 73.8% من المريضات قد أظهرن تقدم فى مدة أقل من 6 أشهر للحالات المتلقية العلاج القائم على مركبات البلاتين أوالمركبات الأخرى, 71.6% من متلقيات العلاج البلاتينى أظهرت مقاومة للبلاتين ووجود قيمة p=0.018.<br/>أيضا معدل البقاء على قيد الحياة بدون تقدم لجميع الحالات بعد تلقى الخط الأول كان 22 شهرا م مقارنة بالخط الثانى الذى كان 4 أشهر فقط.<br/>الحالات التى أظهرت تحسسية لمركبات البلاتين فى مدة تزيد عن 24 شهرا, كان متوسط معدل البقاء على قيد الحياة بدون تقدم أطول من الحالات التى اظهرت تحسسية للبلاتين فى مدة تزيد 12 شهرا حتى 24 شهرا والحالات التى أظهرت تحسسا جزئيا حيث كان متوسط البقاء على قيد الحياة دون تقدم 27 شهرا و 16 شهرا على التوالى وأظهرت وجود قيمة p<0.001. على العكس من ذلك, فإن معدل البقاء على قيد الحياة دون تقدم للخط الثانى القائم على البلاتين, 53 حالة تقدمت فى مدة أقل من ستة أشهر حيث كان المعدل شهرين فقط وقيمة p=0.001 و21 حالة تقدمت فى مدة تزيد عن 6 أشهر , كان معدل البقاء دون تقدم لديهم 15 شهرا.<br/>كان متوسط معدل البقاء على قيد الحياة بشكل عام لجميع الحالات 79 شهرا حيث أن معدل البقاء على قيد الحياة بشكل عام فى أول عامين وصل إلى 100 % وفى السنة الثالثة 84.6 % وبعد خمس سنوات 67.9%. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
ovarian cancer |
| Source of heading or term |
qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
ovary |
| -- |
platinum |
| -- |
sensitive |
| -- |
recurrent |
| -- |
metastatic |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Alfred Elias Namour |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Abdelhamid M.F. Abdelhamid |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Eman Deusoky Taha |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2023 |
| Supervisory body |
Alfred Elias Namour |
| -- |
Abdelhamid M.F. Abdelhamid |
| -- |
Eman Deusoky Taha |
| Universities |
Cairo University |
| Faculties |
National Cancer Institute |
| Department |
Department of Medical Oncology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |
